[go: up one dir, main page]

WO2014118735A1 - Formulation destinée, par exemple, à être utilisée dans le traitement de la grippe et de rhumes - Google Patents

Formulation destinée, par exemple, à être utilisée dans le traitement de la grippe et de rhumes Download PDF

Info

Publication number
WO2014118735A1
WO2014118735A1 PCT/IB2014/058681 IB2014058681W WO2014118735A1 WO 2014118735 A1 WO2014118735 A1 WO 2014118735A1 IB 2014058681 W IB2014058681 W IB 2014058681W WO 2014118735 A1 WO2014118735 A1 WO 2014118735A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
vitamin
flu
treatment
colds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/058681
Other languages
English (en)
Inventor
Christopher Francis BENNETT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2014118735A1 publication Critical patent/WO2014118735A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

  • This invention relates to a formulation, e.g. for use in the treatment of flu and colds.
  • Flu Flu is a prevalent illness, very common in Winter seasons but also at other times of the year. No treatments are considered to be very effective and antibiotics have no effect against viruses, although they may prevent and treat secondary bacterial infections. During global pandemics, hundreds of thousands, if not many millions of patients, may suffer fatal consequences. During normal flu outbreaks, the cost to economies is considerable in terms of lost production and heavy demands on hospitals.
  • Echinacea has been considered by some, especially herbalists, to be a remedy for infections; however, results are often conflicting and can be unconvincing.
  • a formulation comprising Echinacea, selenium and Vitamin D for use in the treatment of flu, colds and mild chest and lung infections.
  • a formulation comprising Echinacea, selenium and Vitamin D3 for use in the treatment of flu, colds and mild chest and lung infections. • 5. A formulation comprising Echinacea, selenium and Vitamin D and Vitamin C for use in the treatment of flu, colds and mild chest and lung infections.
  • a formulation comprising Echinacea, selenium and Vitamin D3 and Vitamin C for use in the treatment of flu, colds and mild chest and lung infections.
  • a formulation comprising Echinacea, selenium and Vitamin D3, Vitamin C and a multivitamin formulation for use in the treatment of flu, colds and mild chest and lung infections.
  • Vitamin D comprises Vitamin D3.
  • Embodiments of the invention provide a formulation for use in the treatment of flu, colds, mild chest and lung infections, that may also assist in reducing bacterial antibiotic resistance development, and economic burdens of flu.
  • inventive formulation have proved effective to the inventor on numerous occasions in self experimentation where flu symptoms were progressing with mild aches and pains, mild fevers and fatigue.
  • Early treatment in particular, terminated progression of the illness with rapid recovery, but therapeutic effects have also been seen in more advanced stages; however, in cases of pneumonia and worsening or severe asthma, patients should consult medical advice with some urgency.
  • Echinacea purpurea 800 mg
  • Vitamin D3 25 micro grammes
  • Vitamin C 500mg
  • selenium 100mg
  • a multi vitamin supplement international standard daily dose formulation
  • inventive formulations may provide a first line therapy prior to antibiotic use should this become necessary. In this way, the development of resistance could be combated.
  • a nasal preparation of this formulation can be used for colds where substantial mucous and debris in the nasal passages may prevent the usual medicinal compounds from penetrating effectively.
  • a nasal cold formulation is of benefit for a dual therapy approach.
  • Vitamin D As noted above, there is a synergistic effect between the Vitamin D and any one or more of the other claimed ingredients. Whereas Vitamin D on its own gives a slight therapy for various medical conditions, and this is not as great as, for example, Vitamin C, the present inventor on the basis of personal research and experience worked out that the use of Vitamin D in conjunction with the other claimed ingredient/s should have a synergistic effect, and when testing this found the effect was in fact much greater than he had thought likely. There are many substances which could have been used with the other claimed ingredients, and all are related to ameliorating various medical conditions, or simply improving general healthiness, so that it is not obvious to try any particular one of them. Indeed, over a long period, i.e.
  • Vitamin D has been tried as one of a large number of trace organic substances used in the diet to improve health generally, as part of a dietary supplement, but not in any way for use in treatment of any illness, and moreover not one that is specifically used and synergistically or even therapeutically effective in conjunction with any of the other ingredients in such a supplement, which must therefore be considered as contributing each in its own individual way to general healthiness.
  • Vitamin D in a synergistic and therapeutic quantity came as quite a surprise, far exceeding the inventor's expectations, and even more so for the particular named maladies, which seem to have closely related characteristics. This is exemplified in the following table, extracted from the inventor's records of experiments: TABLE
  • FV Flu vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une formulation comportant une combinaison thérapeutique et synergique d'échinacée et de vitamine D (de préférence la vitamine D3), comportant de préférence également un ou plusieurs parmi le sélénium, la vitamine C et une formulation multivitaminée, destinée à être utilisée de préférence en tant que médicament, de préférence sous une forme de préparation nasale, de préférence pour utilisation dans le traitement de la grippe, de rhumes, d'infections thoraciques légères et/ou d'infections pulmonaires légères, de préférence pour une utilisation dans un traitement thérapeutique double, de préférence pour une utilisation dans un régime de dosage à être pris deux fois par jour.
PCT/IB2014/058681 2013-02-01 2014-01-30 Formulation destinée, par exemple, à être utilisée dans le traitement de la grippe et de rhumes Ceased WO2014118735A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201301877A GB2510402B (en) 2013-02-01 2013-02-01 A formulation for the treatment of flu, colds, and mild chest and lung infections
GB1301877.5 2013-02-01

Publications (1)

Publication Number Publication Date
WO2014118735A1 true WO2014118735A1 (fr) 2014-08-07

Family

ID=47988617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/058681 Ceased WO2014118735A1 (fr) 2013-02-01 2014-01-30 Formulation destinée, par exemple, à être utilisée dans le traitement de la grippe et de rhumes

Country Status (2)

Country Link
GB (1) GB2510402B (fr)
WO (1) WO2014118735A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770217A (en) * 1997-07-02 1998-06-23 Atlatl, Inc. Dietary supplement for hematological, immune and appetite enhancement
CN1879788A (zh) * 2006-05-03 2006-12-20 苟春虎 病毒清胶囊
US20080242741A1 (en) * 2007-03-30 2008-10-02 Wayne Jeffrey Perry Intranasal drug delivery system
CN101756238A (zh) * 2010-01-22 2010-06-30 郭景龙 一种具有补充微量元素作用的食品
US8273380B1 (en) * 2009-05-19 2012-09-25 Jetway Inc. Fortified beverage for minimizing and/or preventing jet lag
WO2013003689A2 (fr) * 2011-06-30 2013-01-03 Nitromega Corp. Compositions contenant des nitro-acides gras

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632459B2 (en) * 2000-12-11 2003-10-14 Nutricia N.V. Chlorogenic acid and an analog thereof for immune system stimulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770217A (en) * 1997-07-02 1998-06-23 Atlatl, Inc. Dietary supplement for hematological, immune and appetite enhancement
CN1879788A (zh) * 2006-05-03 2006-12-20 苟春虎 病毒清胶囊
US20080242741A1 (en) * 2007-03-30 2008-10-02 Wayne Jeffrey Perry Intranasal drug delivery system
US8273380B1 (en) * 2009-05-19 2012-09-25 Jetway Inc. Fortified beverage for minimizing and/or preventing jet lag
CN101756238A (zh) * 2010-01-22 2010-06-30 郭景龙 一种具有补充微量元素作用的食品
WO2013003689A2 (fr) * 2011-06-30 2013-01-03 Nitromega Corp. Compositions contenant des nitro-acides gras

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Get the facts. The flu, the common cold, and complementary health practices.", February 2012 (2012-02-01), pages 1 - 9, XP002722103, Retrieved from the Internet <URL:http://www.champ-program.org/static/GTF_Flu%20and%20Comp%20Health%20Pract_nccam.pdf> [retrieved on 20140321] *
JAMIESON NATRURAL SOURCES: "ZINC LOZENGES WITH ECHINACEA, VITAMINS C & D HONEY LEMON", 24 August 2012 (2012-08-24), XP002722102, Retrieved from the Internet <URL:http://www.jamiesonvitamins.com/files/2655%20-%20Zinc%20Lozenges%20with%20Vitamin%20C%20&%20D,%20Echinacea%20-%20Honey%20Lemon_0.pdf> [retrieved on 20140321] *

Also Published As

Publication number Publication date
GB201301877D0 (en) 2013-03-20
GB2510402B (en) 2015-05-06
GB2510402A (en) 2014-08-06

Similar Documents

Publication Publication Date Title
Bionorica Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis
Kucukoner et al. Complementary and alternative medicine usage in cancer patients in southeast of Turkey
JP2016505050A5 (fr)
Basisht et al. Management of rheumatoid arthritis (Aamavata) using symbiohealth healthcare system
US20240115590A1 (en) Compositions and therapeutic methods for treating chronic sequalae following viral infections
WO2014118735A1 (fr) Formulation destinée, par exemple, à être utilisée dans le traitement de la grippe et de rhumes
WO2020208659A1 (fr) Composition d&#39;immunostimulation antibactérienne et antivirale d&#39;extraits d&#39;herbes dans des rapports synergiques
CN105451749B (zh) 吸附雄蜂幼虫匀浆和维生素d3或d族维生素和/或其活性代谢物在病毒性疾病的预防和治疗中的应用
US20190247360A1 (en) Pharmaceutical Composition for Treating Bacterial and Viral infections
Ranade Monotherapy with Kutaj ParpatiIs Effective in reducing Irritable Bowel Syndrome(IBS) Symptoms–A Randomized controlled, parallel group trial
Ghosh et al. Two more cases of pregabalin dependence: The pandora's box is open and needs serious attention
RU2456006C1 (ru) Способ лечения больных туберкулезом легких
RU2136305C1 (ru) Комплексное лекарственное средство
Wiriyachitra et al. ByeByeHIV with Thai Innovation
Lee et al. Flu for you? The common cold, influenza, and traditional medicine
JP2009263384A (ja) Ｉ型アレルギー性疾患のアトピー性皮膚炎の症状を抑制するための内服薬
Baek et al. Multicenter, Prospective Study to Investigate the Efficacy and Safety of Intravenous-Immunoglobulin Therapy in Elderly Patients with Diffuse Large B Cell Lymphoma Treated with R-Mini-CHOP
Kim et al. Analysis of Recent Clinical Studies to Establish Korean Herbal Medicine Clinical Trial Guidelines for the Common Cold
Restrepo Use of Alternative Medicine During the COVID-19 Pandemic: An International Survey
Alangari To IV or Not to IV: The Science Behind Intravenous Vitamin Therapy
CN102293786B (zh) 治疗无病菌伤风感冒的药物组合物
Tauleha et al. Treatment of Patients with Flu Like Syndrome-Case Series
Oates Complementary medicines for upper respiratory tract infections in children
Pantuso Intravenous Nutrient Therapies—Worth the Cost?
Gupta et al. Role of Medications in Burning Mouth Syndrome: A Review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14706952

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14706952

Country of ref document: EP

Kind code of ref document: A1